Mdm2 antagonizes the tumor suppressor p53. Targeting the Mdm2-p53 interaction represents an attractive approach for the treatment of cancers with functional p53. Investigating mechanisms underlying Mdm2-p53 regulation is therefore important. The scaffold protein β-arrestin2 (β-arr2) regulates tumor suppressor p53 by counteracting Mdm2. β-arr2 nucleocytoplasmic shuttling displaces Mdm2 from the nucleus to the cytoplasm resulting in enhanced p53 signaling. β-arr2 is constitutively exported from the nucleus, via a nuclear export signal, but mechanisms regulating its nuclear entry are not completely elucidated. β-arr2 can be SUMOylated, but no information is available on how SUMO may regulate β-arr2 nucleocytoplasmic shuttling. While we found β-arr2 SUMOylation to be dispensable for nuclear import, we identified a non-covalent interaction between SUMO and β-arr2, via a SUMO interaction motif (SIM), that is required for β-arr2 cytonuclear trafficking. This SIM promotes association of β-arr2 with the multimolecular RanBP2/RanGAP1-SUMO nucleocytoplasmic transport hub that resides on the cytoplasmic filaments of the nuclear pore complex. Depletion of RanBP2/RanGAP1-SUMO levels result in defective β-arr2 nuclear entry. Mutation of the SIM inhibits β-arr2 nuclear import, its ability to delocalize Mdm2 from the nucleus to the cytoplasm and enhanced p53 signaling in lung and breast tumor cell lines. Thus, a β-arr2 SIM nuclear entry checkpoint, coupled with active β-arr2 nuclear export, regulates its cytonuclear trafficking function to control the Mdm2-p53 signaling axis.
Initially discovered for the roles they play in the regulation of G protein-coupled receptors (GPCRs), the β-arrestins (β-arr1 and β-arr2) have now been shown to act as scaffolding hubs that control multiple signaling pathways [1,2,3]. Through their scaffolding properties β-arrs dynamically regulate the activity and/or subcellular distribution of non-GPCR protein partners such as ERK1/2 [4, 5] JNK3 , Mdm2 [7,8,9], PTEN [10,11,12], and FAK . While strong sequence homology exists between β-arr1 and β-arr2 they display different subcellular distributions [9, 14]. Whereas β-arr1 is found in both the nucleus and cytoplasm at steady state, β-arr2 shows an apparent cytoplasmic distribution. We previously showed that β-arr2 is constitutively excluded from the nucleus by a leptomycin B (LMB)-sensitive pathway driven by a nuclear export signal (NES) that is absent in β-arr1 . We also found that β-arr2 is actively imported into the nucleus, indicating that it undergoes constitutive nucleocytoplasmic shuttling . β-arr2 shuttling displaces nuclear partners, such as JNK3 and Mdm2, from the nucleus to the cytoplasm [9, 14]. In the case of Mdm2, its β-arr2-mediated delocalization results in increased p53 signaling and cell cycle arrest . In contrast to the well-characterized nuclear export mechanism of β-arr2 the entry mechanism(s) of β-arr2 into the nucleus are not completely elucidated.
β-arr2 can be SUMOylated [15, 16], but no information is available on how SUMO may regulate β-arr2 nucleocytoplasmic trafficking. SUMOylation is a key dynamic regulatory posttranslational modification that impacts the activity and localization of protein targets including into the nucleus [17,18,19]. These functional consequences are generally due to modification in protein–protein interactions caused by SUMOylation. Akin to the situation with the ubiquitination pathway, SUMOylation involves a series of sequential enzymatic reactions ultimately leading to covalent conjugation of the 12 kDa protein SUMO on a lysine residue contained within a SUMOylation site (ψ-K-X-E; ψ, a bulky aliphatic residue, typically L, I, or V) on a target protein [17, 18, 20]. There are four SUMO isoforms in mammals: SUMO1, SUMO2, and SUMO3 are expressed ubiquitously, whereas SUMO4 displays tissue restricted expression and it is not clear whether it is conjugated to cellular proteins . SUMO2 and SUMO3 display 97% homology and contain internal SUMOylation sites allowing them to form poly-SUMO chains. SUMO1 shares 45% homology with SUMO2/3 . SUMOylation is reversible with SUMO-modified targets being subject to cleavage of the isopeptide bond by SUMO-specific proteases that release SUMO molecules that become available for further SUMOylation cycles. SUMOylated proteins can establish non-covalent interaction with protein partners via SUMO interaction motifs (SIMs). Identified via two-hybrid screening and biophysical studies, SIMs are composed of a short stretch of hydrophobic residues (generally V/I-V/I-X-V/I) flanked N- or C-terminally by serine residues and/or several acidic residues [17, 22]. When bound to SUMO, SIMs adopt a parallel or antiparallel β-strand conformation that permits the hydrophobic side chains of the SIM to interact with a hydrophobic pocket on the surface of SUMO. The acidic flanking residues in the SIM form electrostatic interactions with a basic interface on SUMO, and thus also contribute to the SUMO–SIM interaction. SIMs can be involved in cis-SUMOylation or in recruitment/targeting of SIM-containing proteins to SUMOylated partners .
Using various in vitro and cell-based approaches, we have characterized both a SUMOylation site and SIM in human β-arr2. Whereas β-arr2 SUMOylation is not required for nuclear import, mutation of the SIM prevents β-arr2 nuclear import. The SIM promotes association of β-arr2 with the multimolecular RanBP2/RanGAP1-SUMO nucleocytoplasmic transport hub and depletion of this complex inhibits β-arr2 nuclear import. The β-arr2∆SIM mutant loses its ability to delocalize Mdm2 from the nucleus to the cytoplasm with functional consequences for p53 activity. Combined, our data reveal that a SUMO–SIM nuclear entry checkpoint, coupled with the nuclear export function of β-arr2, cooperate to regulate its cytonuclear trafficking function and subsequent control of the Mdm2-p53 pathway.
Human β-arr2 is SUMOylated at lysine 295
To investigate the potential role of SUMO in the nucleocytoplasmic trafficking action of β-arr2, we first searched for potential SUMOylation sites within human β-arr2. Ubc9 fusion-directed SUMOylation (UFDS) experiments , which permit efficient and selective protein SUMOylation, were conducted by cloning the E2 conjugase Ubc9 coding sequence upstream of the open reading frame of β-arr2 with a C-terminal FLAG-tag, generating a coding sequence for a Ubc9-β-arr2-FLAG fusion protein (Fig. 1a). The fusion protein was expressed in HeLa cells in the presence of HA-SUMO1 or HA-SUMO2. Immunoprecipitations of the protein extracts using anti-FLAG antibodies followed by western blotting with anti-FLAG antibodies revealed the presence of a molecular weight (MW) band of ∼100 kDa corresponding to the Ubc9-β-arr2-FLAG fusion conjugated with HA-SUMO1 or HA-SUMO2 (Fig. 1b, c, lanes 2). The fused Ubc9 catalyzed SUMOylation of β-arr2, as the active site mutant Ubc9C93S fused to β-arr2 (Fig. 1a) failed to promote β-arr2 SUMOylation in the presence of either SUMO1 or SUMO2 (Fig. 1b, c, lanes 3). Similar results were obtained with the fusions in β-arr1/2 knockout-mouse embryonic fibroblasts (Fig. S1). The expected MW of native β-arr2 is 55 kDa. Following highly denaturing lysis, affinity pulldown with Ni-NTA resin greatly enriched SUMOylated human β-arr2 with a MW of ∼75 kDa corresponding to β-arr2 covalently conjugated with one molecule of SUMO2 in HEK-293 cells expressing exogenous native β-arr2, Ubc9, and His-SUMO2, or FLAG-tagged β-arr2, Ubc9, and His-SUMO2 (Fig. 1d, e, right lanes). SUMOylated β-arr2 was not observed in control cells lacking His-SUMO2 (Fig. 1d, e, left lanes). Similar results were obtained using a yellow fluorescent protein (YFP)-tagged form of β-arr2 (Fig. 1f, MW band at ∼100 kDa).
Human β-arr2 is a 409 amino acid protein composed of N- and C-globular domains linked together by a short hinge region, and a flexible regulatory C-terminal tail (Fig. 2a). To screen for a SUMO acceptor site(s) in β-arr2, a library of overlapping peptides (25-mers), each shifted by five amino acids across the entire sequence of β-arr2 (Fig. 2a), was SPOT-synthesized on cellulose membranes. The peptide arrays were subjected to in vitro SUMOylation assays using a SUMO assay mix containing recombinant forms of E1-activase, E2 conjugase Ubc9, SUMO1–SUMO3, and Mg-ATP solution. Control arrays were performed using SUMO assay mixtures that omitted Ubc9. The arrays were then probed with anti-SUMO antibodies and SUMOylated peptides were identified as dark spots. Using this approach, three consecutive SUMOylated peptides were identified comprising amino acids T276-G310 (Figs. 2b and S2a) that were absent in the control arrays. These peptides contained a consensus SUMOylation motif in β-arr2 294-L-K-H-E-297 that has previously been documented [15, 16]. Confirming that K295 is indeed SUMOylated in the peptides, its mutation to alanine in a “progeny” 25-mer containing amino acids 276–300 inhibited SUMOylation (Figs. 2c and S2b). To confirm the SUMO acceptor site in cells, HEK-293 cells were co-transfected with YFP-β-arr2 or mutant YFP-β-arr2K295R in the presence of Myc-Ubc9 and His-SUMO2. While a ∼100 kDa band of SUMOylated YFP-β-arr2 was observed in Ni-NTA experiments in cells expressing wild-type β-arr2 (Fig. 2d, lane 1), this band was lost with the YFP-β-arr2K295R mutant (Fig. 2d, lane 2), consistent with this being a major SUMOylation site for β-arr2. Taken together, the above findings indicate that β-arr2 is SUMOylated both in vitro and in cells, and that K295, located in the regulatory “lariat loop” of the C-domain of β-arr2 (Fig. 2e), represents a major SUMO conjugation site contained within a consensus SUMOylation motif.
Human β-arr2 contains a SIM in its N-domain
In addition to SUMOylation sites for covalent SUMO conjugation on lysine residues, SIMs exist that mediate non-covalent interaction between SUMO and SIM-containing proteins. We used a Joined Advanced Sumoylation Site and SIM Analyzer (JASSA) program , which predicts SIMs, to analyze the primary sequence of β-arr2. A potential SIM was predicted in the N-domain of β-arr2 between amino acids 41 and 44: 41-V-V-L-V-44 (Fig. 3a, b). Figure 3a shows the alignment of the potential SIM sequence in β-arr2 against other known SIMs found in Daxx, RanBP2, PML-III, and PIAS1. In addition, the sequence in β-arr2 also contains two aspartic acid residues juxtaposed to the hydrophobic core (Fig. 3a, b), another important feature of functional SIMs. To test whether the potential SIM in β-arr2 is capable of non-covalent interaction with SUMO, we carried out pulldown experiments using SUMO1 and SUMO2 proteins coupled to agarose beads. Whereas wild-type β-arr2 bound to both SUMO1 and SUMO2 beads, a β-arr2∆SIM mutant with the 41-V-V-L-V-44 sequence mutated to 41-A-A-L-A-44 displayed greatly decreased binding (Fig. 3c). Thus, the SIM domain in β-arr2 is functional and provides non-covalent interaction with both SUMO1 and SUMO2.
β-arr2 SIM is required for nuclear import
β-arr2 is actively imported into the nucleus and subsequently excluded from the nuclear compartment via active nuclear export . As SUMOylation and non-covalent SUMO interactions are both known to impact protein targeting to the nucleus, we next investigated their possible involvement in the coordination of β-arr2 nucleocytoplasmic trafficking. HeLa cells were transfected with YFP-tagged forms of wild-type β-arr2, SUMOylation mutant (β-arr2K295R) or SIM mutant (β-arr2∆SIM) (Fig. 4a). The cells were then incubated with vehicle or LMB, a drug that specifically inhibits nuclear export of proteins containing leucine-rich NES through inactivation of CRM1/exportin1 . All fusions demonstrated a cytoplasmic distribution at steady state (Fig. 4b). As expected, a 1-h incubation with LMB elicited wild-type β-arr2 nuclear accumulation (Fig. 4b); β-arr2K295R also accumulated in the nucleus in the presence of LMB, demonstrating that SUMOylation on K295 is not required for nuclear import. In contrast, the β-arr2∆SIM mutant failed to accumulate in the nucleus suggesting a default in its nuclear import. Similar results were obtained with non-tagged β-arr2∆SIM, FLAG-tagged β-arr2∆SIM, and mCherry-tagged β-arr2∆SIM (Fig. S3). Live cell imaging in cells transfected with YFP-tagged forms of β-arr2 corroborated results obtained in fixed cells: β-arr2 progressively accumulated in the nucleus during LMB incubation, whereas β-arr2∆SIM did not (Fig. 4c, d), confirming that this mutant presents a defect in nuclear import. Despite this defect in nuclear import, control endocytosis experiments showed that β-arr2∆SIM is still functional as it was able to promote internalization of the GPCR V2 vasopressin receptor (Fig. S4a, b).
SIMs can promote in cis SUMOylation of protein targets and this can occur on lysine residues that do not lie in strict consensus SUMOylation sequences . To rule out that potential additional minor SUMOylation on a secondary lysine in β-arr2 could contribute to nuclear import the β-arr2 primary sequence was analyzed using the JASSA program . In addition to the major K295 site, K11, K25, K53, K158, K293, and K400 were predicted as potential SUMOylation conjugation sites (Fig. 5a). We mutated these lysine residues to arginine either individually, or in combination with the K295R mutation, and tested their impact on nuclear import by incubating HeLa cells expressing the mutant forms of β-arr2 with LMB for 1 h. All mutants accumulated in the nucleus, like K295R, ruling out the possibility that they are implicated in nuclear import (Figs. 5a, b and S5). Finally, we also created a SUMO1-β-arr2∆SIM fusion tagged with YFP, to determine if SUMO fused to β-arr2∆SIM could promote nuclear import. In the presence of LMB this fusion also failed to accumulate in the nucleus, in contrast to a fusion of β-arr2 with the nuclear localization signal (NLS) of SV40, which was able to rescue β-arr2∆SIM nuclear import (Fig. 5c). We next tested the effect of the β-arr2∆SIM mutation in a context where nuclear export of β-arr2 is inhibited through mutation of its NES (L394A). As expected YFP-β-arr2∆NES strongly accumulated in the nucleus, however, the ∆SIM∆NES mutant did not, again confirming the importance of the β-arr2 SIM in nuclear import (Fig. 5d). Similar results were obtained with fractionation experiments, showing marked enrichment of YFP-β-arr2∆NES in the nuclear fraction, whereas YFP-β-arr2∆SIM∆NES, like wild-type β-arr2, was not (Fig. 5e). We also used enhanced bystander bioluminescence resonance energy transfer (ebBRET), based on energy transfer between the naturally occurring chromophores luciferase (Rluc) and green fluorescent protein (rGFP) from Renilla  to monitor nuclear accumulation of β-arr2. For this, rGFP was targeted to the nucleus through fusion of an NLS (rGFP-NLS) and relative nuclear residency of Rluc-β-arr2 fusions was assessed by their ability to generate BRET signals (Fig. 5f). Rluc-β-arr2∆NES generated a stronger BRET signal compared to wild type in agreement with its expected nuclear localization (Fig. 5f). The ∆SIM∆NES mutant displayed a marked decrease in BRET compared to ∆NES indicating reduced nuclear accumulation.
The RanBP2/RanGAP1-SUMO complex gates β-arr2 nuclear entry
The above results indicate that whereas SUMOylation is not required for β-arr2 nuclear import, a non-covalent interaction of the β-arr2 SIM with a SUMOylated protein partner may contribute to its nuclear import. Interestingly, we found that β-arr2 associates with the nucleoporin RanBP2 and RanGAP1-SUMO1 (Fig. 6a), components of a multimolecular SUMO E3 ligase complex that resides on the cytoplasmic filaments of the nuclear pore complex. This complex is involved in substrate SUMOylation and acts as a hub for nucleocytoplasmic transport [27, 28]. RanBP2 is a 358-kDa protein that contains multiple domains including several FG repeats, four Ran-binding domains, and a region that interacts with RanGAP1 [29,30,31,32]. The interaction of RanGAP1 with RanBP2 requires RanGAP1 SUMOylation . When the SIM in β-arr2 is mutated there is a marked reduction in coimmunoprecipitation of both RanGAP1-SUMO1 and RanBP2 with β-arr2, indicating the SIM is important for RanBP2 and RanGAP1-SUMO1 association with β-arr2 (Fig. 6a). To determine if RanBP2 may play a role in β-arr2 nuclear import, we subjected HeLa cells to RanBP2 siRNA treatment and subsequently transfected the cells with mCherry-β-arr2∆NES. Both RanBP2 and RanGAP1-SUMO1 levels were significantly reduced compared to control cells (Fig. 6b) as previously observed . Under these conditions Cherry-β-arr2∆NES shifted from a nuclear to cytoplasmic distribution demonstrating that the RanBP2/RanGAP1-SUMO1 complex plays an important role in promoting β-arr2 nuclear import. These results indicate that the β-arr2 SIM targets β-arr2 to the RanBP2/RanGAP1-SUMO1 complex, which is involved in stimulation of β-arr2 nuclear entry.
Coordinated nuclear import and export of β-arr2 regulates Mdm2 subcellular localization and p53 activity
The nucleocytoplasmic shuttling function of β-arr2 displaces nuclear binding cargoes from the nucleus to the cytoplasm. It was previously demonstrated that displacement of Mdm2, the major negative regulator of p53, from the nucleus to the cytoplasm results in increased p53 activity . We anticipated that a functional SIM would be essential for Mdm2 displacement by β-arr2. In HEK-293 cells transfected with wild-type β-arr2, GFP-Mdm2 was displaced from the nucleus to the cytoplasm, unlike control cells, where GFP-Mdm2 remained nuclear (Fig. 7a, b). Quantification of Mdm2 displacement by β-arr2 demonstrated ∼60% of Mdm2 cytoplasmic relocalization: in ∼10% of cells Mdm2 was predominantly cytoplasmic and in ∼50% partly cytoplasmic, in agreement with previous studies  (Fig. 7c). In the presence of β-arr2∆SIM, the distribution of Mdm2 was similar to control Cherry/Mdm2 expressing cells (Fig. 7a–c). This indicates that due to defective nuclear import, β-arr2∆SIM fails to displace Mdm2 from the nucleus to the cytosol. From a functional viewpoint with regard to Mdm2 displacement, the β-arr2∆SIM therefore behaves like the β-arr2∆NES mutant, which enters in the nucleus but cannot displace Mdm2 due to its defective nuclear export (Fig. 7a–c). The SUMOylation K295R mutant of β-arr2 was still able to displace Mdm2 in line with its normal capacity to shuttle through the nucleus (Fig. 7a–c). Therefore, the SIM in β-arr2, coupled with its nuclear export function, combine to regulate β-arr2 cytonuclear trafficking function with consequences for Mdm2 subcellular localization.
To determine functional consequences of the defect in cytonuclear shuttling found with β-arr2∆SIM on p53 signaling, we first used a H1299 non-small cell lung carcinoma cell line (p53-null) engineered to express p53 using the TETON system . We confirmed that the β-arr2∆SIM defect in nuclear import was also found in these H1299-p53-TETON cells (Fig. 8a). We next transfected H1299-p53-TETON cells with a plasmid coding for luciferase under the control of multiple p53 response elements. As expected, incubation of the cells with doxycycline, to induce p53 expression comparative to endogenous levels found in MCF-7 breast cancer cells carrying TP53 (Fig. S6a), robustly stimulated the luciferase signal, which was markedly reduced by exogenous Mdm2 (Fig. 8b). When β-arr2 was co-transfected with Mdm2, there was a significant increase in p53-dependent luciferase activity compared to Mdm2 alone. However, with the β-arr2∆SIM mutant, which is defective in displacing Mdm2 to the cytoplasm (Fig. 7a–c), no significant increase in p53-dependent activity was observed. This indicates that β-arr2∆SIM failed to rescue Mdm2-mediated inhibition of p53 activity.
As an additional cancer cell model, we used MCF-7 cells with endogenous levels of β-arr2, SUMO1, SUMO2, Ubc9, RanBP2, SUMO-RanGAP, Mdm2, and p53 (Fig. S6b) to investigate the effect of β-arr2∆SIM versus wild-type β-arr2 on p53 signaling. We observed a similar defect in β-arr2∆SIM nuclear import in MCF-7 cells (Fig. 8c), to that documented in HeLa, HEK, and H1299-p53-TETON cells. Finally, we performed p53-dependent gene reporter experiments in MCF-7 cells. An enhancing effect on p53 signaling by wild-type Rluc-tagged β-arr2, expressed at comparative levels to endogenous β-arr2 (Fig. S6c), was observed (Fig. 8d) and this effect was lost with β-arr2∆SIM. Taken together, the above data therefore demonstrate the importance of the SIM in β-arr2 for enhancing p53 function in different cancer cell types.
Mdm2 is the principal negative regulator of p53. Investigating mechanisms underlying Mdm2 regulation is therefore important in understanding p53 biology. β-arr2 nucleocytoplasmic shuttling serves to titrate Mdm2 from the nucleus to the cytoplasm to enhance p53 signaling . Under steady-state conditions this is a receptor-independent signaling mode of β-arr2. While the active nuclear export mechanism of β-arr2, due to the presence of a NES in its C-terminal tail, has been well characterized [9, 14], the mechanism(s) involved in its nuclear import are not completely elucidated. Previous studies have suggested that the N-domain is likely to play an important role in β-arr2 nuclear import [9, 14]. Here, we demonstrate that SUMO orchestrates β-arr2 cytonuclear traffic. Whereas β-arr2 SUMOylation is not required for β-arr2 nuclear import, a SIM in the N-terminus of β-arr2 is involved in its nuclear import. Mutation of the SIM inhibits β-arr2 association with the RanBP2/RanGAP1-SUMO1 nucleocytoplasmic transport hub, and β-arr2 nuclear import. As a consequence, the ability of β-arr2 to titrate Mdm2 from the nucleus to the cytoplasm and effect on p53 signaling is impaired. Our data therefore unveil that a SUMO–SIM nuclear entry checkpoint, coupled with the nuclear export function of β-arr2, regulates its cytonuclear trafficking function to control the Mdm2-p53 loop.
We confirmed that K295 is a major SUMOylation site in human β-arr2. Previous studies of β-arr2 SUMOylation have shown that bovine β-arr2 is SUMOylated on both lysines K295 and K400 but that K400 represents the main SUMOylation site in this species . Inhibition of bovine β-arr2 SUMOylation decreased its association with the endocytic partner β2-adaptin and attenuated β2-AR endocytosis . These data suggest that β-arr2 SUMOylation enhances its binding to β2-adaptin to promote the canonical function of β-arr2 in GPCR endocytosis. Alignment of the bovine and human sequences around K400, however, demonstrates that the human sequence does not fit a strict consensus SUMOylation site here. A subsequent study using human β-arr2 demonstrated that, in contrast to bovine β-arr2, the main SUMOylation site resides at K295 . SUMOylation on this site was found to inhibit β-arr2 binding to TRAF6, permitting enhanced TRAF6 oligomerization and autoubiquitination, and promoting TRAF6-mediated NF-κB signaling . Our results therefore agree with the study on human β-arr2 and confirm K295 as a main SUMOylation site. We found that SUMOylation of β-arr2, however, was not essential for its nuclear import. This finding does not, however, rule out potential intranuclear roles for β-arr2 SUMOylation.
We also identified and characterized a SIM in the N-terminal domain of β-arr2 that we found was required for nuclear delivery. Similar to the role for the β-arr2 SIM in promoting nuclear delivery, SIMs have also been proposed to participate in the nuclear import/accumulation of several other proteins to date. These include the vaccinia virus protein E3 , the Epstein–Barr virus protein kinase BGLF4 , the viral restriction factor TRIM5α , and the MAPK p38 . This suggests that SIM-SUMO mediated transport may be a wider phenomenon involved in nuclear delivery of protein cargoes. SIMs promote recruitment/targeting of SIM-containing proteins to SUMOylated partners. For example, the transcriptional corepressor Daxx contains a SIM that is crucial for subnuclear targeting of Daxx to PML oncogenic domains and for the transrepression of several SUMOylated transcription factors [17, 39]. Our results point toward a targeting role of the SIM in β-arr2 to RanBP2/RanGAP-SUMO1, which forms part of a SUMO E3 ligase complex, localized at the cytoplasmic nuclear pore complex . It is involved in the SUMOylation of certain substrates including Ran-GDP  and provides a hub for nucleocytoplasmic transport . A study investigating a nuclear import enhancement role by RanBP2 analyzed the distribution of ~200 nuclear proteins following RanBP2 depletion . The vast majority did not change subcellular distribution upon RanBP2 depletion, but around 5% were clearly affected, demonstrating cytoplasmic accumulation due to defective nuclear import. RanBP2 can therefore act as a platform for nuclear import for a subset of import cargos . Our results demonstrating cytoplasmic accumulation of β-arr2∆NES following RanBP2 depletion clearly indicate that this nucleoporin is required for β-arr2 nuclear entry. It was proposed that RanBP2 can enhance nuclear import by at least two mechanisms. First, it reduces the active concentration of import receptors required for efficient transport [41, 42] and second, import receptor-independent interaction of selected cargos with RanBP2 can increase efficiency of nuclear import . This suggests that β-arr2 nuclear import probably involves multiple steps coordinated by RanBP2. Indeed, a recent study identified a NLS in β-arr2 and importin β1-dependent nuclear import . This suggests that β-arr2 has dual nuclear entry signals similar to what has been documented with the nuclear protease Calpain 5 . RanBP2 serves as a binding site for importin β1 keeping the transport receptor in association with the nuclear pore complex. RanBP2 therefore likely acts as a hub to coordinate spatiotemporal regulation of β-arr2 nuclear import occurring through dual nuclear entry motifs. In summary, our findings demonstrate that the β-arr2 SIM targets it to the RanBP2/RanGAP-SUMO1 complex, which gates β-arr2 nuclear entry.
As mutation of the SIM inhibits β-arr2 nuclear import, its ability to delocalize Mdm2 from the nucleus to the cytoplasm and effect on enhanced p53 signaling is impaired. The ∆SIM mutant therefore gives rise to the same impaired p53 signaling effect as the ∆NES mutant, which also fails to displace Mdm2 from the nucleus . Our results uncovering the critical role of a β-arr2 SIM in its nuclear entry, coupled with the previously characterized export mechanism, generate an emerging picture of regulatory nodes that impact receptor-independent β-arr2-mediated control of the Mdm2/p53 axis. Future studies will be required to determine if β-arr2 cytonuclear shuttling function is altered in cancer settings.
Materials and methods
Reagents, plasmids, and antibodies
A full list of reagents, plasmids, and antibodies is provided in the Supplementary Materials and Methods section.
Cell culture and transfection
Cell culture and transfection conditions are provided in the Supplementary Materials and Methods section.
His-tagged protein purification using Ni-NTA beads
Assay conditions for His-tagged protein purification are provided in the Supplementary Materials and Methods section.
SUMO beads pulldown assay
For isolation and enrichment of SUMO interacting proteins, SUMO agarose beads from ENZO were used. Assay conditions are provided in the Supplementary Materials and Methods section.
SPOT synthesis of peptides
A peptide library of overlapping 25-mers, that scan the entire human β-arr2 sequence, was produced by automatic SPOT synthesis and synthesized on continuous cellulose membrane supports on Whatman 50 cellulose membranes using Fmoc (fluoren-9-ylmethoxycarbonyl) chemistry with the AutoSpot-Robot ASS 222 (Intavis Bioanalytical Instruments), as described previously .
In vitro SUMOylation on β-arr2 peptide arrays
A SUMOylation kit (Biomol) was used according to the manufacturer’s instructions for the SUMOylation of putative SUMO sites contained within the β-arr2 peptide array . The SUMO assay mix was incubated with array membranes at 30 °C with shaking. Membranes were washed with TBS-T (Tris-buffered saline with Tween 20: 137 mM NaCl, 20 mM Tris/HCl, pH7.6, and 0.1% Tween 20) followed by probing the SUMOylated moieties on the peptide array using an anti-SUMO antibody. Control arrays were performed using SUMO assay mixtures that omitted the E2 conjugase Ubc9.
HEK cells were transiently transfected with plasmids as indicated in the figure legends and following lysis subjected to coimmunoprecipitation as detailed in the Supplementary Materials and Methods section.
Live cell imaging and Immunofluorescence
Live cell imaging and immunofluorescence experiments were conducted as previously described . Details are provided in the Supplementary Materials and Methods section.
The details of the flow cytometry assay used to monitor β-arr2-dependent endocytosis of HA-V2R-vYFP have been described previously . Details are provided in the Supplementary Materials and Methods section.
Cytoplasmic and nuclear fractionation
Cytoplasmic and nuclear extracts were prepared from HeLa cells using the Invent Biotechnologies MinuteTM fractionation kit according to the manufacturer’s instructions.
Enhanced bystander bioluminescence resonance energy transfer (ebBRET)
Endocytosis and nuclear localization ebBRET assays were performed in HEK cells and are described in the Supplementary Materials and Methods section.
Gene reporter experiments
H1299-p53-TETON cells and MCF-7 cells were co-transfected with p53-luc (Stratagene), containing 14xp53-response elements, and either pRL.TK (H1299 cells) or Rluc-tagged forms of β-arr2 (MCF-7 cells) using Lipo3000 in 12-well plates. Cells were lyzed using passive lysis buffer (Promega) and both firefly and Renilla luciferase activities detected using the Dual-Luciferase Reporter Assay System (Promega).
The 3D structure used for β-arr2 is PDB:3P2D. Figures were prepared with PyMol Molecular Graphics System, Version 2.0 Schrödinger, LLC.
Data analysis and statistics
Data are represented as mean ± SEM. Statistical analysis was performed using GraphPad Prism using unpaired t-tests or one-way analysis of variance with Tukey’s post hoc test.
Enslen H, Lima-Fernandes E, Scott MG. Arrestins as regulatory hubs in cancer signalling pathways. Handb Exp Pharmacol. 2014;219:405–25.
Laporte SA, Scott MGH. beta-Arrestins: multitask scaffolds orchestrating the where and when in cell signalling. Methods Mol Biol. 2019;1957:9–55.
Peterson YK, Luttrell LM. The diverse roles of arrestin scaffolds in G protein-coupled receptor signaling. Pharmacol Rev. 2017;69:256–97.
Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL, et al. Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci USA. 2001;98:2449–54.
Luttrell LM, Wang J, Plouffe B, Smith JS, Yamani L, Kaur S. et al. Manifold roles of beta-arrestins in GPCR signaling elucidated with siRNA and CRISPR/Cas9. Sci Signal. 2018;11:eaat7650.
McDonald PH, Chow CW, Miller WE, Laporte SA, Field ME, Lin FT, et al. Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science. 2000;290:1574–7.
Boularan C, Scott MG, Bourougaa K, Bellal M, Esteve E, Thuret A, et al. beta-arrestin 2 oligomerization controls the Mdm2-dependent inhibition of p53. Proc Natl Acad Sci USA. 2007;104:18061–6.
Shenoy SK, McDonald PH, Kohout TA, Lefkowitz RJ. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science. 2001;294:1307–13.
Wang P, Wu Y, Ge X, Ma L, Pei G. Subcellular localization of beta-arrestins is determined by their intact N domain and the nuclear export signal at the C terminus. J Biol Chem. 2003;278:11648–53.
Javadi A, Deevi RK, Evergren E, Blondel-Tepaz E, Baillie GS, Scott MG. et al. PTEN controls glandular morphogenesis through a juxtamembrane beta-Arrestin1/ARHGAP21 scaffolding complex. Elife. 2017;6:e24578.
Lima-Fernandes E, Enslen H, Camand E, Kotelevets L, Boularan C, Achour L, et al. Distinct functional outputs of PTEN signalling are controlled by dynamic association with beta-arrestins. EMBO J. 2011;30:2557–68.
Lima-Fernandes E, Misticone S, Boularan C, Paradis JS, Enslen H, Roux PP, et al. A biosensor to monitor dynamic regulation and function of tumour suppressor PTEN in living cells. Nat Commun. 2014;5:4431.
Alexander RA, Lot I, Saha K, Abadie G, Lambert M, Decosta E. et al. Beta-arrestins operate an on/off control switch for focal adhesion kinase activity. Cell Mol Life Sci. 2020;77:5259–79.
Scott MG, Le Rouzic E, Perianin A, Pierotti V, Enslen H, Benichou S, et al. Differential nucleocytoplasmic shuttling of beta-arrestins. Characterization of a leucine-rich nuclear export signal in beta-arrestin2. J Biol Chem. 2002;277:37693–701.
Wyatt D, Malik R, Vesecky AC, Marchese A. Small ubiquitin-like modifier modification of arrestin-3 regulates receptor trafficking. J Biol Chem. 2011;286:3884–93.
Xiao N, Li H, Mei W, Cheng J. SUMOylation attenuates human beta-arrestin 2 inhibition of IL-1R/TRAF6 signaling. J Biol Chem. 2015;290:1927–35.
Flotho A, Melchior F. Sumoylation: a regulatory protein modification in health and disease. Annu Rev Biochem. 2013;82:357–85.
Geiss-Friedlander R, Melchior F. Concepts in sumoylation: a decade on. Nat Rev Mol Cell Biol. 2007;8:947–56.
Hay RT. SUMO: a history of modification. Mol Cell. 2005;18:1–12.
Rodriguez MS, Dargemont C, Hay RT. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J Biol Chem. 2001;276:12654–9.
Guo D, Li M, Zhang Y, Yang P, Eckenrode S, Hopkins D, et al. A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes. Nat Genet. 2004;36:837–41.
Kerscher O. SUMO junction-what’s your function? New insights through SUMO-interacting motifs. EMBO Rep. 2007;8:550–5.
Jakobs A, Koehnke J, Himstedt F, Funk M, Korn B, Gaestel M, et al. Ubc9 fusion-directed SUMOylation (UFDS): a method to analyze function of protein SUMOylation. Nat Methods. 2007;4:245–50.
Beauclair G, Bridier-Nahmias A, Zagury JF, Saib A, Zamborlini A. JASSA: a comprehensive tool for prediction of SUMOylation sites and SIMs. Bioinformatics. 2015;31:3483–91.
Kudo N, Matsumori N, Taoka H, Fujiwara D, Schreiner EP, Wolff B, et al. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA. 1999;96:9112–7.
Namkung Y, Le Gouill C, Lukashova V, Kobayashi H, Hogue M, Khoury E, et al. Monitoring G protein-coupled receptor and beta-arrestin trafficking in live cells using enhanced bystander BRET. Nat Commun. 2016;7:12178.
Sakin V, Richter SM, Hsiao HH, Urlaub H, Melchior F. Sumoylation of the GTPase Ran by the RanBP2 SUMO E3 Ligase Complex. J Biol Chem. 2015;290:23589–602.
Walde S, Thakar K, Hutten S, Spillner C, Nath A, Rothbauer U, et al. The nucleoporin Nup358/RanBP2 promotes nuclear import in a cargo- and transport receptor-specific manner. Traffic. 2012;13:218–33.
Mahajan R, Delphin C, Guan T, Gerace L, Melchior F. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell. 1997;88:97–107.
Matunis MJ, Wu J, Blobel G. SUMO-1 modification and its role in targeting the Ran GTPase-activating protein, RanGAP1, to the nuclear pore complex. J Cell Biol. 1998;140:499–509.
Wu J, Matunis MJ, Kraemer D, Blobel G, Coutavas E. Nup358, a cytoplasmically exposed nucleoporin with peptide repeats, Ran-GTP binding sites, zinc fingers, a cyclophilin A homologous domain, and a leucine-rich region. J Biol Chem. 1995;270:14209–13.
Yokoyama N, Hayashi N, Seki T, Pante N, Ohba T, Nishii K, et al. A giant nucleopore protein that binds Ran/TC4. Nature. 1995;376:184–8.
Hashizume C, Kobayashi A, Wong RW. Down-modulation of nucleoporin RanBP2/Nup358 impaired chromosomal alignment and induced mitotic catastrophe. Cell Death Dis. 2013;4:e854.
Monteith JA, Mellert H, Sammons MA, Kuswanto LA, Sykes SM, Resnick-Silverman L, et al. A rare DNA contact mutation in cancer confers p53 gain-of-function and tumor cell survival via TNFAIP8 induction. Mol Oncol. 2016;10:1207–20.
Gonzalez-Santamaria J, Campagna M, Garcia MA, Marcos-Villar L, Gonzalez D, Gallego P, et al. Regulation of vaccinia virus E3 protein by small ubiquitin-like modifier proteins. J Virol. 2011;85:12890–900.
Li R, Wang L, Liao G, Guzzo CM, Matunis MJ, Zhu H, et al. SUMO binding by the Epstein-Barr virus protein kinase BGLF4 is crucial for BGLF4 function. J Virol. 2012;86:5412–21.
Brandariz-Nunez A, Roa A, Valle-Casuso JC, Biris N, Ivanov D, Diaz-Griffero F. Contribution of SUMO-interacting motifs and SUMOylation to the antiretroviral properties of TRIM5alpha. Virology. 2013;435:463–71.
Wang PY, Hsu PI, Wu DC, Chen TC, Jarman AP, Powell LM. et al. SUMOs mediate the nuclear transfer of p38 and p-p38 during helicobacter pylori infection. Int J Mol Sci. 2018;19:2482
Lin DY, Huang YS, Jeng JC, Kuo HY, Chang CC, Chao TT, et al. Role of SUMO-interacting motif in Daxx SUMO modification, subnuclear localization, and repression of sumoylated transcription factors. Mol Cell. 2006;24:341–54.
Werner A, Flotho A, Melchior F. The RanBP2/RanGAP1*SUMO1/Ubc9 complex is a multisubunit SUMO E3 ligase. Mol Cell. 2012;46:287–98.
Hutten S, Flotho A, Melchior F, Kehlenbach RH. The Nup358-RanGAP complex is required for efficient importin alpha/beta-dependent nuclear import. Mol Biol Cell. 2008;19:2300–10.
Hutten S, Walde S, Spillner C, Hauber J, Kehlenbach RH. The nuclear pore component Nup358 promotes transportin-dependent nuclear import. J Cell Sci. 2009;122:1100–10.
Zhang X, Min X, Wang S, Sun N, Kim KM. Mdm2-mediated ubiquitination of beta-arrestin2 in the nucleus occurs in a Gbetagamma- and clathrin-dependent manner. Biochem Pharm. 2020;178:114049.
Singh R, Brewer MK, Mashburn CB, Lou D, Bondada V, Graham B, et al. Calpain 5 is highly expressed in the central nervous system (CNS), carries dual nuclear localization signals, and is associated with nuclear promyelocytic leukemia protein bodies. J Biol Chem. 2014;289:19383–94.
Bolger GB, Baillie GS, Li X, Lynch MJ, Herzyk P, Mohamed A, et al. Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5. Biochem J. 2006;398:23–36.
Li X, Vadrevu S, Dunlop A, Day J, Advant N, Troeger J, et al. Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK. Biochem J. 2010;428:55–65.
Blondel-Tepaz E, Guilbert T, Scott MGH. Methods to investigate the nucleocytoplasmic shuttling properties of beta-arrestins. Methods Mol Biol. 2019;1957:251–69.
Paradis JS, Ly S, Blondel-Tepaz E, Galan JA, Beautrait A, Scott MG, et al. Receptor sequestration in response to beta-arrestin-2 phosphorylation by ERK1/2 governs steady-state levels of GPCR cell-surface expression. Proc Natl Acad Sci USA. 2015;112:E5160–8.
We thank Dr. A. Benmerah for helpful discussion, Dr. J. Liotard for excellent technical assistance, and the Institut Cochin Imaging (IMAG’IC) and Sequencing platforms (GENOM’IC). The Institut Cochin lab is part of the Who am I? laboratory of excellence (grant ANR-11-LABX-0071), funded by the “Investments for the Future” program operated by The French National Research Agency (grant ANR-11-IDEX-0005-01). This work was funded by grants from the Fondation ARC pour la Recherche sur le Cancer (“Projet ARC” to MGHS), Ligue contre le Cancer (to MGHS), Royal Society (“International Joint Project Scheme” to MGHS and GSB), France Canada Research Fund (to MGHS and SA), CNRS, and INSERM. The work in the laboratory of M.B. was supported by a CIHR Foundation (FDN148431) grant. M.B. holds the Canada Research Chair in Signal transduction and Molecular Pharmacology. EBT was funded by MESR and Fondation ARC pour la Recherche sur le Cancer doctoral fellowships.
Conflict of interest
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Blondel-Tepaz, E., Leverve, M., Sokrat, B. et al. The RanBP2/RanGAP1-SUMO complex gates β-arrestin2 nuclear entry to regulate the Mdm2-p53 signaling axis. Oncogene 40, 2243–2257 (2021). https://doi.org/10.1038/s41388-021-01704-w